- Home
- RDWR vs URGN Comparison
RDWR vs URGN Comparison
Compare RDWR & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDWR
- URGN
- Stock Information
- Founded
- RDWR 1996
- URGN 2004
- Country
- RDWR Israel
- URGN United States
- Employees
- RDWR N/A
- URGN N/A
- Industry
- RDWR EDP Services
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- RDWR Technology
- URGN Health Care
- Exchange
- RDWR Nasdaq
- URGN Nasdaq
- Market Cap
- RDWR 849.8M
- URGN 673.5M
- IPO Year
- RDWR 1999
- URGN 2017
- Fundamental
- Price
- RDWR $21.04
- URGN $13.33
- Analyst Decision
- RDWR Buy
- URGN Strong Buy
- Analyst Count
- RDWR 2
- URGN 4
- Target Price
- RDWR $23.00
- URGN $48.38
- AVG Volume (30 Days)
- RDWR 128.3K
- URGN 516.1K
- Earning Date
- RDWR 10-30-2024
- URGN 08-13-2024
- Dividend Yield
- RDWR N/A
- URGN N/A
- EPS Growth
- RDWR N/A
- URGN N/A
- EPS
- RDWR N/A
- URGN N/A
- Revenue
- RDWR $259,005,000.00
- URGN $85,011,000.00
- Revenue This Year
- RDWR $5.93
- URGN $16.49
- Revenue Next Year
- RDWR $6.81
- URGN $57.58
- P/E Ratio
- RDWR N/A
- URGN N/A
- Revenue Growth
- RDWR N/A
- URGN 17.22
- 52 Week Low
- RDWR $13.53
- URGN $10.60
- 52 Week High
- RDWR $23.05
- URGN $20.70
- Technical
- Relative Strength Index (RSI)
- RDWR 49.11
- URGN 39.63
- Support Level
- RDWR $19.72
- URGN $12.83
- Resistance Level
- RDWR $22.87
- URGN $13.90
- Average True Range (ATR)
- RDWR 0.52
- URGN 0.58
- MACD
- RDWR -0.16
- URGN -0.01
- Stochastic Oscillator
- RDWR 48.37
- URGN 29.60
About RDWR Radware Ltd.
Radware Ltd provides cyber security and application delivery solutions. The company provides solutions for cloud, on-premises, and software-defined data centers (SDDC). The solutions of the company secure the digital experience by providing infrastructure, application, and network protection and availability services to enterprises globally. The business segments of the company are Radware's Core Business and The Hawks' Business. The company derives maximum revenue from Radware's Core Business. The company generates maximum revenue from the United States.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.